Literature DB >> 21998180

Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma?

R Sayer1, J Paul, P W Tuke, S Hargreaves, M Noursadeghi, R S Tedder, P Grant, S G Edwards, R F Miller.   

Abstract

We measured plasma human herpesvirus 8 (HHV8) DNA load in consecutive patients presenting with HIV-associated multicentric Castleman disease (MCD) and in contemporaneous patients who had Kaposi sarcoma (KS), lymphoma or other diagnoses. All 11 patients with MCD had detectable plasma HHV8 DNA compared with 18 (72%) of 25 patients with KS, none with lymphoma and one of 38 patients with other diagnoses. Detectable plasma HHV8 DNA levels were higher among MCD patients, median (interquartile range [IQR]) = 43,500 (5200-150,000) copies/mL, when compared with those with KS, median (IQR) = 320 (167-822) copies/mL and those with lymphoma and other diagnoses (one-way analysis of variance; P = 0.0303). Using receiver operating characteristic analysis, a cut-off of >1000 copies HHV8 DNA/mL of plasma helped to discriminate between MCD and other diagnoses, with a specificity of 94.7% and a negative predictive value of 97.3%. The level of HHV8 viraemia, while not diagnostic, may aid discrimination between patients with MCD and those with KS and other systemic illnesses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21998180     DOI: 10.1258/ijsa.2011.010464

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  1 in total

1.  Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A.

Authors:  Kristen M Tamburro; Dongmei Yang; Jessica Poisson; Yuri Fedoriw; Debasmita Roy; Amy Lucas; Sang-Hoon Sin; Nadia Malouf; Vincent Moylan; Blossom Damania; Stephan Moll; Charles van der Horst; Dirk P Dittmer
Journal:  Virology       Date:  2012-08-24       Impact factor: 3.616

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.